Inhibition of leukotriene actions by the calcium channel blocker, nisoldipine.
Nisoldipine, a calcium channel blocker having a highly potent effect on vascular smooth muscle relative to cardiac muscle, was tested to determine its anti-leukotriene properties. Nisoldipine, at concentrations from 1 to 300 ng/ml, significantly attenuated the vasoconstrictor effects of both LTC4 and LTD4 in isolated perfused cat coronary arteries and in isolated Langendorff perfused cat hearts. In isolated perfused coronary arteries, nisoldipine exerted a greater percentage inhibition of LTC4- and LTD4-induced constriction than of the constriction induced by the thromboxane analog, carbocyclic thromboxane A2 (CTA2). In isolated cat lung fragments, higher concentrations of nisoldipine were required to inhibit leukotriene formation (i.e., 10-200 microM). These concentrations of nisoldipine markedly inhibited the formation of the chemotactic leukotriene (LTB4) as well as the peptide leukotrienes (LTC4 and LTD4) stimulated by A-23187. Both types of leukotrienes were inhibited to a comparable degree. Thus, nisoldipine has significant anti-leukotriene actions. At normally employed concentrations, nisoldipine inhibits leukotriene actions on vascular smooth muscle, and at higher concentrations, it inhibits leukotriene formation.
D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002415:Cats; D003331:Coronary Vessels / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D066298:In Vitro Techniques; D007975:Leukotriene B4 / Q000096:biosynthesis; D008168:Lung / Q000378:metabolism; D008297:Male; D009543:Nifedipine / Q000031:analogs & derivatives* / Q000494:pharmacology; D015737:Nisoldipine; D013189:SRS-A / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D014661:Vasoconstriction / Q000187:drug effects
D002121:Calcium Channel Blockers; D013189:SRS-A; D007975:Leukotriene B4; D015737:Nisoldipine; D009543:Nifedipine